1422355-59-6 Usage
General Description
The chemical compound "(3beta)-3-(3-Carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-alpha,21-dioxo-28-norlup-18-ene-17-acetamide" is a complex molecule with a cyclopropyl group and a chlorophenyl group attached to a norlup-18-ene core structure. It also contains a carboxy and methyl oxobutoxy functional group. (3beta)-3-(3-Carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-alpha,21-dioxo-28-norlup-18-ene-17-acetamide is classified as an acetamide derivative and is likely to have biological activity due to its structural similarity to natural steroids. The specific pharmacological and physiological effects of this compound are not known and further research is needed to determine its potential uses in medicine or other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1422355-59-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,2,3,5 and 5 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1422355-59:
(9*1)+(8*4)+(7*2)+(6*2)+(5*3)+(4*5)+(3*5)+(2*5)+(1*9)=136
136 % 10 = 6
So 1422355-59-6 is a valid CAS Registry Number.
1422355-59-6Relevant articles and documents
Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms
Tang, Jun,Jones, Stacey A.,Jeffrey, Jerry L.,Miranda, Sonia R.,Galardi, Cristin M.,Irlbeck, David M.,Brown, Kevin W.,McDanal, Charlene B.,Johns, Brian A.
, p. 2689 - 2694 (2017/05/29)
A new class of betulin-derived α-keto amides was identified as HIV-1 maturation inhibitors. Through lead optimization, GSK8999 was identified with IC50 values of 17?nM, 23?nM, 25?nM, and 8?nM for wild type, Q369H, V370A, and T371A respectively. When tested in a panel of 62 HIV-1 isolates covering a diversity of CA-SP1 genotypes including A, AE, B, C, and G using a PBMC based assay, GSK8999 was potent against 57 of 62 isolates demonstrating an improvement over the first generation maturation inhibitor BVM. The data disclosed here also demonstrated that the new α-keto amide GSK8999 has a mechanism of action consistent with inhibition of the proteolytic cleavage of CA-SP1.